Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930014/S161

AcrySof Single-Piece IOL (SA60AT); AcrySof IQ Aspheric IOL (SN60WF); AcrySof Aspheric UV-Absorbing IOL (SA60WF); AcrySof

Alcon Laboratories, Inc. · Decision date Apr 30, 2026

FDA DECISIONP930014/S161

What did the FDA approve?

FDA records P930014/S161 as a supplement to PMA P930014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Apr 30, 2026.

FDA approval order statement

approval application (PMA) 180-day supplement, which requested approval for a new packaging configuration, automation of the primary and secondary packaging processes, and updates to shelf-life and storage conditions of the AcrySof IOLs (storage condition temperatures from 45 °C to 30 °C), and Clareon IOLs (to extend the shelf life from four (4) years to five (5) years at the temperature of 30 °C) in Alcons manufacturing facilities in West Virginia, USA and Cork, Ireland.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Ophthalmic
Decision date
Apr 30, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P930014/S161
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
APPR
Decision date
Apr 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P930014/S157 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  2. P930014/S158 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  3. P930014/S159 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  4. P930014/S161 received

    Application receipt date recorded by FDA.

  5. P930014/S160 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  6. P930014/S162 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  7. P930014/S161 · FDA decision

    Normal 180 Day Track

  8. P930014/S165 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

  9. P930014/S163 · Related supplement

    Acrosof Posterior Chamber Intraocular Lens

  10. P930014/S164 · Related supplement

    AcrySof Posterior Chamber Intraocular Lens and Delivery Systems

Timeline entries are records held by MedtechLedger for P930014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P930014

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy. Dr., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records